Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER-Panc: Platform Trial for Localized Pancreatic Cancer
NCT04481204Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2023
- Primary completion
- Apr 2026
- Modality
- Orthosteric Ligands, DNA Intercalators/Alkylators, Polymer-based Nanoparticles
01
Overview
Phase 2, randomised, open-label trial in pancreatic ductal adenocarcinoma (PDAC) (6 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Major pathological response rate at 12 weeks and Disease control rate at 6 months. Planned start Apr 2023; status: withdrawn.
02
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04481204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04481204.